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Abstract
Background: Methylation of CpG sites in genomic DNA plays an important role in gene regulation and especially in
gene silencing. We have reported mechanisms of epigenetic regulation for expression of mucins, which are markers of
malignancy potential and early detection of human neoplasms. Epigenetic changes in promoter regions appear to be
the first step in expression of mucins. Thus, detection of promoter methylation status is important for early diagnosis of
cancer, monitoring of tumor behavior, and evaluating the response of tumors to targeted therapy. However,
conventional analytical methods for DNA methylation require a large amount of DNA and have low sensitivity.
Methods: Here, we report a modified version of the bisulfite-DGGE (denaturing gradient gel electrophoresis) using
a nested PCR approach. We designated this method as methylation specific electrophoresis (MSE). The MSE
method is comprised of the following steps: (a) bisulfite treatment of genomic DNA, (b) amplification of the target
DNA by a nested PCR approach and (c) applying to DGGE. To examine whether the MSE method is able to
analyze DNA methylation of mucin genes in various samples, we apply it to DNA obtained from state cell lines,
ethanol-fixed colonic crypts and human pancreatic juices.
Result: The MSE method greatly decreases the amount of input DNA. The lower detection limit for distinguishing
different methylation status is < 0.1% and the detectable minimum amount of DNA is 20 pg, which can be obtained
from only a few cells. We also show that MSE can be used for analysis of challenging samples such as human isolated
colonic crypts or human pancreatic juices, from which only a small amount of DNA can be extracted.
Conclusions: The MSE method can provide a qualitative information of methylated sequence profile. The MSE
method allows sensitive and specific analysis of the DNA methylation pattern of almost any block of multiple CpG
sites. The MSE method can be applied to analysis of DNA methylation status in many different clinical samples, and
this may facilitate identification of new risk markers.
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Background
The gene expression profile of a cancer specimen is a
valuable source of biological information that has poten-
tial clinical utility [1]. However, RNA or DNA of a suffi-
cient quality and quantity for analysis may not be
recoverable from clinical samples. Methylation of CpG
sites in genomic DNA plays an important role in gene
regulation, especially in gene silencing, and the promoter
region of a transcribed gene is generally hypomethylated.
Mechanisms of epigenetic regulation for expression of
v a r i o u sm u c i n s( M U C 1 ,M U C 2 ,M U C 3 A ,M U C 4 ,
MUC5AC and MUC17) are reported [2-10]. Further-
more, abnormal epigenetic changes appear to be early
“seeds of methylation” that precede detection of genetic
mutations [11,12]. Thus, a method for detecting altera-
tion of methylation status could be a valuable tool for
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and assessing the response of tumors to targeted therapy.
Several methods for analyzing DNA methylation have
been developed, each of which ideally requires a large
amount of high-quality DNA, such as that obtained from
cultured cells or fresh tissue samples. However, DNA
recovered from clinical samples such as urine sediment,
saliva, sputum, bronchial washing fluid, bile or pancreatic
juice is often limited in quantity or degraded. Develop-
ment of DNA methylation as a marker involves examina-
tion of the correlation between the extent of DNA
methylation and pathological findings, and such studies
have been performed using human fluid samples such as
pancreatic juice, bile juice and blood [13-18]. These stu-
dies have often used the methylation specific PCR (MSP),
methylight or massARRAY analysis. However, as shown
in Figure 1, in analysis of crude samples, MSP and
methylight may indicate that “a region was 50% methy-
lated” while massARRAY indicates that “all CpG sites
were 50% methylated”. Thus, the methylation pattern
might be A (extreme pattern) or B (variable pattern).
These 2 patterns are very different, but current methods
cannot distinguish between A and B. This is a pitfall for
accurate diagnosis in clinical application of DNA methy-
lation analysis. Thus, a DNA methylation pattern with
information on content is very important for evaluation
of the DNA methylation status.
To resolve this issue, we developed a modified version
of the bisulfite-denaturing gradient gel electrophoresis
(DGGE) [19] which used a nested PCR approach to
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pattern, since the DGGE can detect disparity of single
mutation in the same size PCR product. We designated
this method as methylation specific electrophoresis
(MSE). The MSE method allows sensitive and specific
analysis of the DNA methylation pattern of almost any
block of multiple CpG sites. We applied this method to
analyze the DNA methylation patterns of promoter
regions of various mucins in 12 cancer cell lines. In addi-
tion, we examined the DNA methylation patterns of the
promoter region of MUC1 in samples of human isolated
colonic crypts, and also examined human pancreatic
juices collected from the patients with pancreatic ductal
adenocarcinoma (PDAC) having a very poor prognosis
and from the patients with intraductal papillary muci-
nous neoplasm (IPMN) having a favorable prognosis.
Methods
Cell lines
Human pancreatic carcinoma cell lines HPAF II, BxPC3,
PANC1; human breast cancer cell lines MCF-7, T-47D,
MDA-MB-453; and human colon adenocarcinoma cell
lines Caco2 and LS174T were o b t a i n e df r o mA m e r i c a n
Type Culture Collection. HPAF II, MCF-7, LS174T, and
Caco2 cells were cultured in Eagle’s MEM (Sigma-
Aldrich), PANC1 cells were cultured in DMEM (Sigma-
Aldrich), BxPC3 and T-47D cells were cultured in RPMI
1640 (Sigma-Aldrich), and MDA-MB-453 cells were cul-
tured in Leibovitz’s L-15 medium (Invitrogen, Carlsbad,
CA, USA). All media were supplemented with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA, USA), 100 U/
ml penicillin (Sigma-Aldrich) and 100 μg/ml streptomy-
cin (Sigma-Aldrich).
Isolation of human colonic crypts
Fresh normal and tumor tissue samples were obtained
from colorectal carcinoma specimens that were obtained
surgically at Iwate Medical College Hospital. Normal
colonic mucosa was taken from an area distant from the
tumor. The tumor samples were obtained from the
tumor-rich area of carcinomas. Crypt isolation from the
normal and neoplastic mucosa was performed as pre-
viously reported [20-22]. Briefly, fresh normal mucosae
and tumors were minced with a razor into minute
pieces and then incubated at 37°C for 30 minutes in cal-
cium- and magnesium-free Hanks’ balanced salt solution
(CMF) containing 30 mmol/L ethylene-diaminetetraace-
tic acid (EDTA). Following this procedure, the tissue
was stirred in CMF for 30-40 minutes. Normal and neo-
plastic glands were separated from the lamina propria
mucosa or fibrous stroma. The isolated crypts were
immediately fixed in 70% ethanol and stored at 4°C
until used for DNA and RNA extraction, and were also
embedded in paraffin for immunohistochemical staining.
All studies using human materials in this article were
approved by the ethical committees of Kagoshima Uni-
versity hospital and other hospitals.
Pancreatic juice
After completion of endoscopic retrograde pancreato-
graphy, pancreatic juice was collected using endoscopic
nasopancreatic drainage (ENPD) or pancreatic stenting
in 2 patients with PDAC and 5 patients with IPMN at
Osaka Medical College Hospital [23]. Collection of the
samples was approved by the ethical committee of the
h o s p i t a la n di n f o r m e dc o n s e n tw a so b t a i n e df r o me a c h
patient. All studies using human materials in this article
were approved by the ethical committees of Kagoshima
University hospital and other hospitals.
Extraction and quantification of mRNA
Extraction of RNA
Total RNA was extracted from the cell lines, human
colonic crypts and pancreatic juices using a RNeasy
Mini kit (QIAGEN, Chuo-ku, Tokyo, Japan). Total RNA
of 1 μg was then reverse transcribed with a High Capa-
city RNA-to-cDNA Kit (Applied Biosystems, Foster City,
CA, USA).
Real time PCR assay
For quantification of MUC1 mRNA in the ethanol-fixed
isolated crypts from human colonic normal mucosa and
carcinoma lesions, the real time PCR assay was per-
formed as described previously [7]. The primers and
probes were designed and synthesized by Applied Bio-
systems. The product number of the Target Assay Mix
used for MUC1 was Hs00410317. Human glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH; product
number 4310884E) was used to calibrate the original
concentration of mRNA; i.e., the concentration of
mRNA in the cell was defined as the ratio of target
mRNA copies versus GAPDH mRNA copies. In this
analysis, data from three separate experiments were
averaged.
RT-PCR
For confirmation of gene expression level in cell lines,
semiquantitative RT-PCR were performed using a Fast
Cycling PCR kit (QIAGEN, Japan). The RT-PCR pro-
ducts were subjected to electrophoresis on 1% agarose
gel. Differentially expressed genes were detected using
the primer pairs (shown in Additional file 1: Table S1).
Extraction of DNA and bisulfite modification
DNA from cell lines, ethanol-fixed human crypt sec-
tions, and pancreatic juice samples was extracted using
aD N e a s yT i s s u eS y s t e m( Q I A G E N ,C h u o - k u ,T o k y o ,
Japan). Bisulfite modification of the genomic DNA was
carried out using an Epitect Bisulfite Kit (QIAGEN,
Chuo-ku, Tokyo, Japan).
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Primer design
The target sequence containing CpG sites important for
expression in respective mucin promoter regions were
determined using a massARRAY analysis that has been
published previously [2-10]. All the PCR primers were
designed to avoid CpG site. The primers are bisulfite
genomic sequencing type (Table 1). In addition, the tar-
get PCR primers were designed to be optimal sample
fragment sizes (100 bp to 700 bp) for DGGE (Table 1B).
Preparation of the samples
In the MSE method, a nested-PCR approach was used. In
the first round of PCR, bisulfite treated DNA was ampli-
fied using the nested primer sets (Table 1A). The cycling
conditions consisted of an initial denaturation step at 95°C
for 5 min, then 40 cycles of 96°C for 5 s, Tm°C for 5 s,
and 68°C for 3 s (the value of Tm shown in Table1). The
information of each PCR product size and primer location
at this initial PCR reaction is shown in Table 2A. For the
second round of PCR, this product was diluted 1:50 in
water, and 2 μl of the dilution were amplified using the
target primer sets (Table 1B). The PCR parameters were
as above, except that the annealing temperatures for the
MUC1, MUC2, MUC3A, MUC4, MUC5AC and MUC17
reactions were 53, 51, 52, 57, 62 and 53°C respectively.
The information of each PCR product size and primer
location at the second PCR reaction is shown in Table 2B.
All steps of PCR were performed using a Fast Cycling
PCR kit (QIAGEN, Japan).
Denaturing gradient gel electrophoresis (DGGE)
After the PCR, DGGE was performed as described by
Schäfer and Muyzer [24] using the D-Code system (Bio-
Rad Laboratories, Hercules, CA, USA). Electrophoresis
was performed with 1-mm thick 10% polyacrylamide gels
(ratio of acrylamide to bisacrylamide, 40:1) submerged in
1Χ TAE buffer (40 mM Tris, 40 mM acetic acid, 1 mM
EDTA, pH 7.5) at a constant temperature of 60°C. PCR
products in amounts ranging from 5 μl were applied to
the individual lanes on the gel. The electrophoresis con-
ditions for the target gene fragment were 14 h at 70 V in
a linear denaturant gradient (MUC1, 30%-40%; MUC2,
25%-35%; MUC3A, 25%-35%; MUC4, 25%-45%;
MUC5AC, 30%-40%; MUC17, 35%-45%). After electro-
phoresis, the gels were incubated for 30 min in Milli-Q
water containing GelRed (dilution 1:10000) (Biotium,
Table 1 Synthetic oligonucleotides used in MSE and conventional bisulfite-DGGE
Primer name sequence Tm
A. The nested PCR primer set
MUC1 Forward: 5’-AAAGGGGGAGGTTAGTTGGA-3’ 63
Reverse: 5’-TACCCCTCACCTATAAACAC-3’
MUC2 Forward: 5’-TTTGGGGTTAGGTTTGGAAG-3’ 59
Reverse: 5’-ACCTTCTTCAAAATAAAACAACC-3’
MUC3A Forward: 5’-TTGAGGGATAGAAGGGGTTTG-3’ 64
Reverse: 5’-AACCCCAACAACTACATAAACCC-3’
MUC4 Forward: 5’-AGAGTAAGGGGTGTATGGGTG-3’ 60
Reverse: 5’-ACTCCACTACCCAACAACTAC-3’
MUC5AC Forward: 5’-AAAGTTTTGGGTGTGTGGAG-3’ 62
Reverse: 5’-ATCAATATCCAACCCCCAAC-3’
MUC17 Forward: 5’-ATAAAGGGGGTGTTTTTGTTAGG-3’ 62
Reverse: 5’-AAACAAACAAAACAAACTAACCCC-3’
B. The target PCR primer set
MUC1 Forward: 5’-[GC CLAMP]AAGAGGTAGGAGGTAGGGGA-3’ 53
Reverse: 5’-AAAACAAAACAAATTCAAAC-3’
MUC2 Forward: 5’-[GC CLAMP]TTTTAGAGTTTGGGTTTTAG-3’ 51
Reverse: 5’-TAACCTAAATACCAACACAC-3’
MUC3A Forward: 5’-[GC CLAMP]TTTTAGGTAGTTTTATGTGG-3’ 52
Reverse: 5’-AACAAAAAACTAAAACAAAAC-3’
MUC4 Forward: 5’-[GC CLAMP] AGGAGAGAAAAGGGTGATTAG -3’ 57
Reverse: 5’-ACTCCACTACCCAACAACTAC-3’
MUC5AC Forward: 5’-[GC CLAMP]TTTATGTTTAGGGGTTTTGG-3’ 62
Reverse: 5’-ACCAACTAACCACCCAAACC-3’
MUC17 Forward: 5’-[GC CLAMP]ATTTTTATGTTTATGGGTTG-3’ 53
Reverse: 5’-ATAATCCCTAACCTTAACATC-3’
*[GC CLAMP]:5’-CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGG-3’
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(ATTO). The emission intensity of the band was mea-
sured using Image J (NIH).
Conventional bisulfite-DGGE for comparison
In the conventional bisulfite-DGGE method, the bisulfite
treated DNA was amplified using the target primer sets
(Table 1B). PCR parameters were as above, except that
the annealing temperatures for the MUC1, MUC2,
MUC3A, MUC4, MUC5AC and MUC17 reactions were
53, 51, 52, 57, 62 and 53°C respectively. Information on
each PCR product size and each primer location is
shown in Table 2B. All steps of PCR were performed
using a Fast Cycling PCR kit (QIAGEN, Japan). After
the PCR, these products were applied to DGGE.
Immunohistochemical staining
MUC1 protein expression was assessed by immunohisto-
chemistry using an anti-MUC1 monoclonal antibody
(MAb) clone 014E (Mab MUC1-014E), which was devel-
oped by Yonezawa et al. [25], in ethanol-fixed paraffin-
embedded 4-μm sections of the isolated human normal
and neoplastic crypts. Immunohistochemistry was per-
formed by the immunoperoxidase method as follows.
Antigen retrieval was performed using CC1 antigen retrie-
val buffer (Ventana Medical Systems, Tucson, AZ, USA)
for all sections. Following incubation with MAb MUC1-
014E (diluted 1:5) in phosphate-buffered saline (PBS, pH
7.4) with 0.1% bovine serum albumin, sections were
stained on a Benchmark XT automated slide stainer using
a diaminobenzidine detection kit (Ventana Medical
Systems).
Results and discussion
MSE approach for MUC1 promoter region
We examined the characteristics of the MSE approach for
MUC1 using cell lines in which the DNA methylation sta-
tus of the MUC1 promoter region has been precisely
defined [7]. First, we made controls of fully methylated
and unmethylated DNA. The completely fully methylated
control DNA was prepared by the treatment using methyl-
transferase (Sss I) on DNA from Caco2 which has the
Table 2 Information of PCR product size and primer location
Primer name location* Product size**
A. The nested PCR primer set
MUC1 Forward: -219 bp to -200 bp 375 bp
Reverse: +156 bp to +137 bp
MUC2 Forward: -460 bp to -441 bp 261 bp
Reverse: -200 bp to -219 bp
MUC3A Forward: -478 bp to -418 bp 495 bp
Reverse: +17 bp to -6 bp
MUC4 Forward: -249 bp to -228 bp 239 bp
Reverse: -30 bp to -11 bp
MUC5AC Forward: -3960 bp to -3941 bp 450 bp
Reverse: -3511 bp to -3530 bp
MUC17 Forward: -383 bp to -361 bp 586 bp
Reverse: +203 bp to +180 bp
B. The target PCR primer set
MUC1 Forward: -124 bp to -15 bp 206 bp
Reverse: +42 bp to +23 bp
MUC2 Forward: -437 bp to -418 bp 256 bp
Reverse: -222 bp to -241 bp
MUC3A Forward: -321 bp to -302 bp 361 bp
Reverse: -10 bp to -31 bp
MUC4 Forward: -194 bp to -173 bp 156 bp
Reverse: -59 bp to -38 bp
MUC5AC Forward: -3842 bp to -3823 bp 225 bp
Reverse: -3658 bp to -3677 bp
MUC17 Forward: -200 bp to -181 bp 312 bp
Reverse: +72 bp to +53 bp
* location*: relative to transcription start site. Product size
**: GC clamp added size
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previous MassARRAY analysis (Additional file 2: Table S2)
[7]. Similarly, the fully unmethylated control DNA was
prepared by PCR for the MUC1 promoter region on DNA
from T-47D which has the lowest methylation status in
the cell lines examined in the previous MassARRAY analy-
sis (Additional file 2: Table S2) [7]. The bisulfite-sequen-
cing analyses for the fully methylated and unmethylated
controls showed clearly defined methylated and unmethy-
lated sequence (Additional file 3: Table S3). The MSE ana-
lyses for the fully methylated and unmethylated controls
showed clearly defined methylated and unmethylated
bands (Additional file 4: Figure S1). This electrophoretic
migration distance depends on mutation (cytosine vs. thy-
mine) in the target sequence, but not on the PCR product
size. Thus, the “methylated sequence” carrying many cyto-
sines shows higher mobility than the “un-methylated
sequence” carrying many thymines which are converted
from cytosines by the bisulfite treatment. For this reason,
the more a band migrates, the higher the band is methy-
lated. In addition, the multiple bands indicate a mix of var-
ious patterns of methylated CpG sequences. This method
provides information on the degree of methylation status
by the migration distance of bands and the variation of
methylated sequences by the numbers of bands, although
it does not provides the individual CpG methylation ratio.
Sensitivity of MSE in MUC1 promoter region analysis
To examine the minimum volume for detection, we eval-
uated 5 concentrations (from 200 ng to 20 pg) of DNA
extracted from the A427 and LS174T. Five concentration
s a m p l e sw e r ep r e p a r e db yat e n - f o l ds e r i a ld i l u t i o no f
initial bisulfite treated DNA sample (200 ng/μl). MSE
was able to analyze 20 pg DNA of the bisulfite-treated
DNA (Figure 2A, upper panel), whereas analysis with
conventional bisulfite-DGGE was unsuccessful at under
200 ng DNA (Figure 2A, lower panel). Thus, MSE
enhanced the overall sensitivity for detection of methy-
lated MUC1 promoter DNA by at least 10,000-fold rela-
tive to conventional bisulfite-DGGE. In addition, we
evaluated 5 concentrations of bisulfite treated DNA
recovered from human pancreatic juice. Five concentra-
tion samples were prepared by a ten-fold serial dilution
of initial bisulfite treated DNA sample (20 ng/μl). MSE
was able to analyze 200 pg DNA of bisulfite-treated DNA
(Additional file 5: Figure S2).
Resolution of MSE in MUC1 promoter region analysis
N e x t ,w ea n a l y z e dD N Ad e r i v e df r o mB x P C 3( t e n d e n c y
for lower methylation of the MUC1 promoter region)
and Panc1 (tendency for higher methylation of the
MUC1 promoter region) (Figure 2B, upper panel).
These 2 cell lines has heterogeneity of methylated CpG
sequence pattern [7]. Thus, BxPC3 shows various bands
which are inclined toward the hypomethylated side.
Similarly, Panc1 shows various bands which are inclined
toward the hypermethylated side. Aggerholm et al
demonstrated a correlation exists between the band
migration and the number of methylated sites in a dena-
turing gradient gel [19]. In addition, we tested MSE on a
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Figure 2 (A) Analysis of the methylation status of A427 (A) and LS174T (L) by MSE and conventional bisulfite-DGGE. (B) Determination
of the resolution of MSE detection. A mixture of a high methylation cell line (Panc1) and a low methylation cell line (BxPC3) was analyzed. The
number shows the BxPC3 contamination ratio. The upper band (arrow) shows the digitalized emission intensity using Image J. On the graph, the
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Y = 243.26X + 187.25; correlation co-efficient: R
2 = 0.993. Data were averaged from 3 separate experiments.
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2B, upper panel). We found that the emission intensity
of the band for the hypo-methylated MUC1 promoter
was directly proportional to the contamination ratio of
hypo-methylated cells (R
2 = 0.993; Figure 2B, lower
panel). MSE can accurately detect a methylation target
at a level of 0.1%. These results indicate that MSE can
detect 3 abnormal cells (un-methylated MUC1 promo-
ter) in 3000 normal (methylated MUC1 promoter) cells.
We have shown that MSE is not only highly specific
and sensitive, but that it also can rapidly detect biologi-
cally relevant information in patient samples. In con-
trast, Li et al. suggested that an optimized MSP assay
was unable to detect methylated templates when the
fraction of methylated fragments was < 6.2% in parallel
assays [26]. MSE provides significant advantages over
the conventional bisulfite- D G G Es i n c eM S Er e q u i r e s
only 200 pg of DNA of low quality, making it suitable
for small biopsies, ethanol-fixed tissue, and clinical fluid
samples.
Application of MSE for promoter regions of various
mucins
To show that the MSE method can be used to analyze
promoter regions of various mucins (MUC1, MUC2,
MUC3A, MUC4, MUC5AC and MUC17), we analyzed
the DNA methylation status in promoter regions that
play key roles in expression of mucins in 12 cancer cell
lines. Expression of mRNA was detected by semiquanti-
tative RT-PCR analysis, with GAPDH mRNA used as a
c o n t r o l .T h ee x p r e s s i o nl e v e lo fm R N As h o w sah i g h
propensity for regulation by DNA methylation [2,4,6-10]
(Figure 3). The results of MSE analysis in each cell line
(Figure 3) were consistent with DNA methylation pat-
terns obtained by massARRAY analysis [2,4,7-10].
Application of MSE for human samples
In ethanol-fixed isolated crypts from human colonic nor-
mal mucosa and carcinoma, the expression level of mRNA
and the DNA methylation status were analyzed. Immuno-
histochemical staining for MUC1 was performed using
serial sections of ethanol-fixed isolated crypts from human
colonic normal mucosa and carcinoma lesions. Both nor-
mal and neoplastic crypts showed a high expression level
of mRNA (Figure 4A) in a real time PCR assay, low
methylation of the MUC1 promoter region in MSE analy-
sis (Figure 4B), and positive MUC1 expression in immu-
nohistochemistry (Figure 4C). All isolated crypt samples
were found to have a hypomethylated MUC1 promoter by
MSE. Similar analysis performed for MUC2 and MUC4
gave similar results (Additional file 6: Figure S3). Thus,
these results suggest that the MSE method allows analysis
of the extent of DNA methylation in ethanol-fixed
sections.
To examine whether the MSE method can be used to
analyze human fluid samples, we applied MSE to analysis
of DNA obtained from human pancreatic juice. Pancreatic
juice samples were collected from 2 patients with PDAC
and 5 patients with IPMN. The amount of recovered DNA
was 2.3 μg (PDAC-1), 2.7 μg (PDAC-2), 904 ng (IPMN-1),
2.3 μg (IPMN-2), 132 ng (IPMN-3), 72 ng (IPMN-4), and
100 ng (IPMN-5). Then, bisulfite treated processing was
performed to the sample of 1 μg (PDAC-1), 1 μg (PDAC-
2), 452 ng (IPMN-1), 1 μg (IPMN-2), 132 ng (IPMN-3),
72 ng (IPMN-4), and 100 ng (IPMN-5), respectively. The
1/20 volume of the bisulfite treated DNA was applied for
Figure 3 MSE analysis of DNA methylation status of MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC17 promoter regions in 12 cell
lines. The results of each mRNA analysis using RT-PCR are shown in the upper row of MSE results. The expression level of GAPDH mRNA in
each cell line was used as a control in the RT-PCR analysis. The methylation pattern of each gene was consistent with the results of massARRAY
analysis [2,4,6-10].
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DNA was recovered in small amounts and/or low quality,
the MSE method was sufficiently robust to allow detailed
analysis of the DNA methylation patterns in all the sam-
ples, and showed significant different patients between
PDAC and IPMN (Figure 5). In contrast, the conventional
bisulfite-DGGE method could not detect the methylation
status in any samples (data not shown). Similar analyses
performed for MUC2 and MUC4 gave similar results
(Additional file 7: Figure S4). Thus, these results indicate
that MSE is applicable for various types of crude samples,
including human fluid samples, whereas the conventional
bisulfite-DGGE method could not detect the methylation
status.
To our knowledge, there is no report describing this
intuitive modification of the bisulfite-DGGE method.
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methylation status of mucin genes for pancreatic juices.
Interestingly, in the pancreatic juice analysis, the electro-
phoresis band pattern of MSE revealed a significant dif-
ference of degree of methylation status in the promoter
region of MUC1, MUC2 or MUC4 between PDAC with
a very poor prognosis and IPMN with a favorable prog-
nosis. A further study is needed to clarify the biological
significance of this observation, but the lower methyla-
tion in PDAC compared to IPMN may provide an
approach for early diagnosis of pancreatic neoplasm.
Conclusions
The MSE method can provide a qualitative information
of methylated sequence profile. The MSE method is a
simple, sensitive, and specific method for determining
the DNA methylation status of almost any CpG island.
Here, we have shown that MSE can be used to analyze
ethanol-fixed samples (human colonic crypts) and
human fluid samples (human pancreatic juice). Thus,
MSE can be applied to analysis of DNA methylation in
many different clinical samples, and this may facilitate
identification of new risk markers.
Additional material
Additional file 1: Table S1. Synthetic oligonucleotides used in RT-PCR.
Additional file 2: Table S2. MassARRAY analysis of MUC1 promoter
region at Caco2 and T-47D.
Additional file 3: Table S3. Sequence of MUC1 promoter region, and
bisulfite-sequence of Sss I treated DNA of Caco2 and PCR amplicon of T-
47D.
Additional file 4: Figure S1. Preparation of fully methylated and
unmethylated controls. The methyltransferase (Sss I) treatment of 1 μg
DNA was performed at 37°C for 4 h. The fully unmethylated control was
construct by PCR with the following primers (forward primer 1: 5’-
CATTATCCAGCCCTCTTATTTCTC-3’ and reverse primer 2: 5’-
ACTTCTCTACAGGACATTTGCTTG-3’) using 20 ng of DNA as template.
Then, these DNA samples were applied to bisulfite treatment.
Additional file 5: Figure S2. Analysis of the methylation status of DNA
extracted from PDAC patient. Five concentration samples were prepared
by a ten-fold serial dilution using initial bisulfite treated DNA sample (20
ng/μl). D.W.: using distilled water; N.T.: using non-bisulfite treated DNA.
Additional file 6: Figure S3. MSE analysis of MUC2 and MUC4 promoter
DNA mathylation status using human colonic normal and neoplastic
crypts. N:normal tissue. T: tumor tissue. All isolated crypt samples showed
high expression levels of MUC2 and MUC4 mRNA and protein.
Additional file 7: Figure S4. MSE analysis of MUC2 and MUC4 promoter
DNA methylation status using human fluid samples. Pancreatic juice
samples were collected from 2 patients with PDAC and 5 patients with
IPMN. The level of methylation in PDAC was significantly lower than that
in IPMN.
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